公开(公告)号：CA2352552C

公开(公告)日：2008-12-02

申请号：CA2352552

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： BERGGREN RANDALL G ,  GALE ROBERT M ,  PLACE VIRGIL A

IPC: A61K9/02 ,  A61K31/5575 ,  A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) containing the agent on its exterior surface or by means of an inserter (27) carrying an agent containing dose of agent (31) which can be displaced into the urethra.

公开(公告)号：NO300083B1

公开(公告)日：1997-04-07

申请号：NO924032

申请日：1992-10-19

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K9/02 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：IE81089B1

公开(公告)日：2000-03-08

申请号：IE133091

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61K9/02 ,  A61M31/00 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：ES2124225T3

公开(公告)日：1999-02-01

申请号：ES91909083

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61K9/02 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/22 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：AT173603T

公开(公告)日：1998-12-15

申请号：AT91909083

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61K9/02 ,  A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/22 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：CA2352552A1

公开(公告)日：1991-10-26

申请号：CA2352552

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： BERGGREN RANDALL G ,  GALE ROBERT M ,  PLACE VIRGIL A

IPC: A61K9/02 ,  A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) containing the agent on its exterior surface or by means of an inserter (27) carrying an agent containing dose of agent (31) which can be displaced into the urethra.

公开(公告)号：FI104946B

公开(公告)日：2000-05-15

申请号：FI924817

申请日：1992-10-23

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61K9/02 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/22 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：DK0526566T3

公开(公告)日：1999-08-09

申请号：DK91909083

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61K9/02 ,  A61P15/12 ,  A61K9/08 ,  A61K9/10 ,  A61K9/22 ,  A61K47/10

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：NZ270871A

公开(公告)日：1999-05-28

申请号：NZ27087191

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K9/02 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：NZ237899A

公开(公告)日：1997-03-24

申请号：NZ23789991

申请日：1991-04-22

Applicant: VIVUS INC SUBSTITUTED FOR ALZA

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61K9/02 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12 ,  A61K45/08 ,  A61F2/26

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.